Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03861481 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
A Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), sponsored by UCB Biopharma S.P.R.L..
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 20
- Study locations
NCT03861481 is a Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) that has completed, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 34 participants, below the 42-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT03861481, a Phase 2 study of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), has completed, sponsored by UCB Biopharma S.P.R.L..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Rozanolixizumab
Study Locations (20)
Other
- Cidp01 101 - Ghent
- Cidp01 102 - Leuven
- Cidp01 103 - Liège
- Cidp01 302 - Copenhagen
- Cidp01 402 - Bordeaux
- Cidp01 404 - Nice
- Cidp01 401 - Strasbourg
- Cidp01 501 - Berlin
- Cidp01 503 - Essen
- Cidp01 505 - Göttingen
- Cidp01 502 - Würzburg
- Cidp01 601 - Amsterdam
- Cidp01 701 - Barcelona
North Carolina
- Cidp01 903 - Charlotte
- Cidp01 912 - Durham
Arizona
- Cidp01 902 - Phoenix
California
- Cidp01 905 - Los Angeles
Florida
- Cidp01 901 - Tampa
Georgia
- Cidp01 907 - Augusta
Kentucky
- Cidp01 911 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2019-03-26 |
| Est. Completion | 2021-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03861481
The ClinicalTrials.gov registry entry for NCT03861481 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 42-participant average among 3 other Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trials with a reported enrollment target (19% lower). The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03861481 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, North Carolina, Arizona.
Frequently Asked Questions
What is clinical trial NCT03861481 about?
NCT03861481 is a clinical study titled "A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy". The purpose of the study is to evaluate clinical efficacy of rozanolixizumab as a treatment for subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
What is the current status of trial NCT03861481?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2019-03-26. Estimated completion is 2021-03-31.
What conditions does trial NCT03861481 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP).
What interventions are being tested in trial NCT03861481?
The interventions under investigation include: Placebo (OTHER), Rozanolixizumab (DRUG).
Who is sponsoring clinical trial NCT03861481?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03861481 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RECRUITING · Phase 2
-
A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
RECRUITING
-
A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.